{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T15:13:03Z","timestamp":1779203583894,"version":"3.51.4"},"reference-count":9,"publisher":"Oxford University Press (OUP)","issue":"6","license":[{"start":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T00:00:00Z","timestamp":1770940800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,5,19]]},"abstract":"<jats:p>This article presents a critical appraisal of \u2018Efficacy and safety of bimekizumab in patients with moderate-to-severe hidradenitis suppurativa (BE-HEARD I and BE-HEARD II): two 48-week, randomized, double-blind, placebo-controlled, multicentre phase III trials\u2019.<\/jats:p>","DOI":"10.1093\/bjd\/ljag051","type":"journal-article","created":{"date-parts":[[2026,2,12]],"date-time":"2026-02-12T12:50:12Z","timestamp":1770900612000},"page":"1064-1066","source":"Crossref","is-referenced-by-count":0,"title":["Two phase III trials of bimekizumab for the treatment of moderate-to-severe hidradenitis suppurativa: a critically appraised research paper"],"prefix":"10.1093","volume":"194","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7126-8384","authenticated-orcid":false,"given":"Rebecca","family":"McCarthy","sequence":"first","affiliation":[{"name":"Blizard Institute, Barts and the London School of Medicine and Dentistry, Queen Mary University of London , London ,","place":["UK"]},{"name":"Department of Dermatology, The Royal London Hospital, Barts Health NHS Trust , London ,","place":["UK"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hans Christian","family":"Ring","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Zealand University Hospital , Roskilde ,","place":["Denmark"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2026,2,13]]},"reference":[{"key":"2026051911002433300_ljag051-B1","doi-asserted-by":"crossref","first-page":"e171","DOI":"10.1111\/bjd.16603","article-title":"Profound consequences of hidradenitis suppurativa: a review","volume":"183","author":"Matusiak","year":"2020","journal-title":"Br J Dermatol"},{"key":"2026051911002433300_ljag051-B2","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1016\/j.jaad.2016.10.042","article-title":"Increased interleukin (IL)-17 serum levels in patients with hidradenitis suppurativa: implications for treatment with anti-IL-17 agents","volume":"76","author":"Matusiak","year":"2017","journal-title":"J Am Acad Dermatol"},{"key":"2026051911002433300_ljag051-B3","doi-asserted-by":"crossref","first-page":"2213","DOI":"10.1016\/j.jaci.2020.12.651","article-title":"Epithelialized tunnels are a source of inflammation in hidradenitis suppurativa","volume":"147","author":"Navrazhina","year":"2021","journal-title":"J Allergy Clin Immunol"},{"key":"2026051911002433300_ljag051-B4","doi-asserted-by":"crossref","first-page":"2504","DOI":"10.1016\/S0140-6736(24)00101-6","article-title":"Efficacy and safety of bimekizumab in patients with moderate-to-severe hidradenitis suppurativa (BE HEARD I and BE HEARD II): two 48-week, randomised, double-blind, placebo-controlled, multicentre phase 3 trials","volume":"403","author":"Kimball","year":"2024","journal-title":"Lancet"},{"key":"2026051911002433300_ljag051-B5"},{"key":"2026051911002433300_ljag051-B6","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1056\/NEJMoa1504370","article-title":"Two phase 3 trials of adalimumab for hidradenitis suppurativa","volume":"375","author":"Kimball","year":"20126","journal-title":"N Engl J Med"},{"key":"2026051911002433300_ljag051-B7","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1016\/S0140-6736(23)00022-3","article-title":"Secukinumab in moderate-to-severe hidradenitis suppurativa (SUNSHINE and SUNRISE): week 16 and week 52 results of two identical, multicentre, randomised, placebo-controlled, double-blind phase 3 trials","volume":"401","author":"Kimball","year":"2023","journal-title":"Lancet"},{"key":"2026051911002433300_ljag051-B8","doi-asserted-by":"crossref","first-page":"726","DOI":"10.7326\/0003-4819-152-11-201006010-00232","article-title":"CONSORT statement: updated guidelines for reporting parallel group randomized trials","volume":"152","author":"Schulz","year":"2010","journal-title":"Ann Intern Med"},{"key":"2026051911002433300_ljag051-B9","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1016\/j.jaad.2015.08.052","article-title":"Correlation of inflammatory serum markers with disease severity in patients with hidradenitis suppurativa (HS)","volume":"73","author":"Hessam","year":"2015","journal-title":"J Am Acad Dermatol"}],"container-title":["British Journal of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/bjd\/advance-article-pdf\/doi\/10.1093\/bjd\/ljag051\/66890879\/ljag051.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/bjd\/article-pdf\/194\/6\/1064\/66890879\/ljag051.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/bjd\/article-pdf\/194\/6\/1064\/66890879\/ljag051.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T15:00:28Z","timestamp":1779202828000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/bjd\/article\/194\/6\/1064\/8482700"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,13]]},"references-count":9,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2026,2,13]]},"published-print":{"date-parts":[[2026,5,19]]}},"URL":"https:\/\/doi.org\/10.1093\/bjd\/ljag051","relation":{},"ISSN":["0007-0963","1365-2133"],"issn-type":[{"value":"0007-0963","type":"print"},{"value":"1365-2133","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,6]]},"published":{"date-parts":[[2026,2,13]]}}}